テネシーにおける転移性癌の臨床試験
テネシー内の拠点で、転移性癌に関する75件の研究が参加者を募集しています。
テネシー内の都市
公式研究テキスト（英語）
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Regional Cancer Center at Johnson City Medical Center, Johnson City
- Ballad Health Cancer Care - Kingsport, Kingsport
- 他3件
被験者募集中第2相
全年齢 · 全性別 · 2026/10/02更新 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Sarah Cannon Research Institute, Nashville
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06465069Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- West Cancer Center, Germantown
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology, Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07562152A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Tennessee Oncology, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06270706A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
- Sarah Cannon Research Institute (SCRI), Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06234605A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Sarah Cannon Research Institute (SCRI), Nashville
被験者募集中第1相
19歳以上 · 全性別 · 2026/10/01更新 · NCT06586957Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- SCRI Oncology Partners, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06625775A Study of ASP3082 in Adults With Advanced Solid Tumors
- Vanderbilt University Medical Center, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/30更新 · NCT05382559Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- University of Tennessee Medical Center, Knoxville
- Henry-Joyce Cancer Clinic, Nashville
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT06943755Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT05803382Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Henry-Joyce Cancer Clinic, Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07222800A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07277413A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- St. Jude Children's Research Hospital, Memphis
被験者募集中第1/2相
25歳以下 · 全性別 · 2026/09/25更新 · NCT04094610Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Tennessee Oncology, PLLC - Chattanooga Downtown, Chattanooga
- Tennessee Oncology, PLLC - Chattanooga - Medical Park II, Chattanooga
- Tennessee Oncology, PLLC - Franklin, Franklin
- 他11件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07222566A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- Henry-Joyce Cancer Clinic, Nashville
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06989437A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
- SCRI Oncology Partners, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07612176A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Chattanooga
- Research Site, Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06103864A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- Sarah Cannon Research Institute, Nashville
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/09/24更新 · NCT05118789A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07218380A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Sarah Cannon Research Institute SCRI, Nashville
- Nashville General Hospital, Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07174336Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Sarah Cannon Research Institue, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06128551A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Vanderbilt University Medical Center, Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07213804AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
- Tennessee Oncology PLLC, Nashville
被験者募集中第1相
18歳〜99歳 · 全性別 · 2026/09/21更新 · NCT07403721A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- Tennessee Oncology, PLLC, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/21更新 · NCT07629960Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Sarah Cannon Research Institute, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT05267626Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- Tennessee Oncology, PLLC- Chattanooga Downtown, Chattanooga
- Tennessee Oncology, PLLC - Chattanooga Med Park II, Chattanooga
- Tennessee Oncology, PLLC - Chattanooga Memorial, Chattanooga
- 他22件
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07227415A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- The West Clinic, PLLC dba West Cancer Center ( Site 0005), Germantown
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT06863272Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
- SCRI Oncology Partners, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT06566079CREO - Microwave Ablation Feasibility Study
- University of Tennessee Medical, Knoxville
被験者募集中
18歳以上 · 全性別 · 2026/09/14更新 · NCT07817147CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- Clinical Study Site, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/10更新 · NCT07335497A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Center, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06440005A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Nashville
被験者募集中第3相
18歳〜130歳 · 全性別 · 2026/09/08更新 · NCT07647328NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies
- Sarah Cannon Research Institute, Nashville
被験者募集中第1相
19歳以上 · 全性別 · 2026/09/08更新 · NCT07563829A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Tennessee Oncology Chattanooga, Chattanooga
- University of Tennessee Medical Center, Knoxville
- Baptist Memorial Hospital-Memphis, Memphis
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06119581A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06561685Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/04更新 · NCT06311214A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
- Sarah Cannon Research Institute - Tennessee Oncology, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/03更新 · NCT07213830A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
- West Cancer Center, Germantown
被験者募集中第1/2相
18歳以上 · 女性 · 2026/09/03更新 · NCT04802759A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
- Sarah Cannon Research Institute-Tennessee Oncology, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/02更新 · NCT04913285ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。